AUGMENTIN INFANT DROPS
Amoxicillin trihydrate - Potassium clavulanate

QUALITATIVE AND QUANTITATIVE COMPOSITION

*AUGMENTIN* infant drops contain 50 mg amoxicillin (as amoxicillin trihydrate) and 12.5 mg clavulanic acid (as potassium clavulanate) per 1 ml.

PHARMACEUTICAL FORM

Dry powder for reconstitution in water, at time of dispensing, to form an oral sugar-free suspension.

CLINICAL PARTICULARS

Indications

*AUGMENTIN* should be used in accordance with local official antibiotic-prescribing guidelines and local susceptibility data.

*AUGMENTIN* infant drops are indicated for short-term treatment of bacterial infections at the following sites:

*Upper respiratory tract infections (including ENT)* e.g. recurrent tonsillitis, sinusitis, otitis media.

*Lower respiratory tract infections* e.g. acute exacerbation of chronic bronchitis, lobar and bronchopneumonia.

*Genito-urinary tract infections* e.g. cystitis, urethritis, pyelonephritis.

*Skin and soft tissue infections*, e.g. boils, abscesses, cellulitis, wound infections.

*Bone and joint infections* e.g. osteomyelitis.

*Other infections* e.g. intra-abdominal sepsis.

Susceptibility to *AUGMENTIN* will vary with geography and time (see Pharmacological Properties, Pharmacodynamics for further information). Local susceptibility data should be consulted where available, and microbiological sampling and susceptibility testing performed where necessary.

Infections caused by amoxicillin-susceptible organisms are amenable to *AUGMENTIN* treatment due to its amoxicillin content. Mixed infections caused by amoxicillin-susceptible organisms in conjunction with *AUGMENTIN*-susceptible ß-lactamase producing organisms may therefore be treated with *AUGMENTIN*. 
Dosage and Administration

The usual recommended daily dosage is 25 mg/kg/day* in divided doses every eight hours.

In more serious infections the dosage may be increased up to 50 mg/kg/day in divided doses every eight hours.

* Each 25 mg AUGMENTIN provides 20 mg amoxicillin and 5 mg clavulanate.

AUGMENTIN infant drops should be administered orally using the supplied syringe doser. The syringe doser is graduated to permit accurate and reproducible volumes to be dispensed. Children should be dosed according to body weight. A similar dose should be administered once every eight hours.

For information, the volumes of AUGMENTIN infant drops which correspond to the weight of a child are shown below:

<table>
<thead>
<tr>
<th>Weight of child (kg)</th>
<th>Volume (ml) of AUGMENTIN infant drops **</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>0.13</td>
</tr>
<tr>
<td>1.5</td>
<td>0.20</td>
</tr>
<tr>
<td>2</td>
<td>0.27</td>
</tr>
<tr>
<td>2.5</td>
<td>0.33</td>
</tr>
<tr>
<td>3</td>
<td>0.40</td>
</tr>
<tr>
<td>3.5</td>
<td>0.47</td>
</tr>
<tr>
<td>4</td>
<td>0.53</td>
</tr>
<tr>
<td>4.5</td>
<td>0.60</td>
</tr>
<tr>
<td>5</td>
<td>0.67</td>
</tr>
<tr>
<td>5.5</td>
<td>0.73</td>
</tr>
<tr>
<td>6</td>
<td>0.80</td>
</tr>
<tr>
<td>6.5</td>
<td>0.87</td>
</tr>
<tr>
<td>7</td>
<td>0.93</td>
</tr>
<tr>
<td>7.5</td>
<td>1.00</td>
</tr>
<tr>
<td>8</td>
<td>1.07</td>
</tr>
<tr>
<td>8.5</td>
<td>1.14</td>
</tr>
<tr>
<td>9</td>
<td>1.20</td>
</tr>
<tr>
<td>9.5</td>
<td>1.27</td>
</tr>
<tr>
<td>10</td>
<td>1.34</td>
</tr>
</tbody>
</table>

** These doses may be doubled in cases of severe infection.
Dosage in renal impairment

<table>
<thead>
<tr>
<th>Mild impairment</th>
<th>Moderate impairment</th>
<th>Severe impairment</th>
</tr>
</thead>
<tbody>
<tr>
<td>(Creatinine clearance &gt;30 ml/min)</td>
<td>(Creatinine clearance 10-30 ml/min)</td>
<td>(Creatinine clearance &lt;10 ml/min)</td>
</tr>
<tr>
<td>No change in dosage, i.e. The recommended dose given 3 times daily#</td>
<td>The recommended dose given twice daily instead of 3 times per day# (maximum 10 ml twice daily)</td>
<td>The recommended dose given once daily instead of 3 times per day# (maximum 10 ml)</td>
</tr>
</tbody>
</table>

# In more serious cases this dose may be doubled.

Dosage in hepatic impairment

Dose with caution; monitor hepatic function at regular intervals.

Administration

To minimise potential gastrointestinal intolerance, administer at the start of a meal. The absorption of AUGMENTIN is optimised when taken at the start of a meal.

Duration of therapy should be appropriate to the indication and should not be extended beyond 14 days without review.

Contraindications

AUGMENTIN is contra-indicated in patients with a history of hypersensitivity to beta-lactams, e.g. penicillins and cephalosporins.

AUGMENTIN is contra-indicated in patients with a previous history of AUGMENTIN-associated jaundice/hepatic dysfunction.

Warnings and Precautions

Before initiating therapy with AUGMENTIN, careful enquiry should be made concerning previous hypersensitivity reactions to penicillins, cephalosporins or other allergens.

Serious and occasionally fatal hypersensitivity reactions (including anaphylactoid and severe cutaneous adverse reactions) have been reported in patients on penicillin therapy. These reactions are more likely to occur in individuals with a history of penicillin hypersensitivity (see Contraindications). If an allergic reaction occurs, AUGMENTIN therapy must be discontinued and appropriate alternative therapy instituted. Serious anaphylactic reactions require immediate emergency treatment with adrenaline. Oxygen, intravenous (i.v.) steroids and airway management (including intubation) may also be required.

AUGMENTIN should be avoided if infectious mononucleosis is suspected since the occurrence of a morbilliform rash has been associated with this condition following the use of amoxicillin.
Prolonged use may also occasionally result in overgrowth of non-susceptible organisms.

Pseudomembranous colitis has been reported with the use of antibiotics and may range in severity from mild to life-threatening. Therefore, it is important to consider its diagnosis in patients who develop diarrhoea during or after antibiotic use. If prolonged or significant diarrhoea occurs or the patient experiences abdominal cramps, treatment should be discontinued immediately and the patient investigated further.

Abnormal prolongation of prothrombin time (increased INR) has been reported rarely in patients receiving AUGMENTIN and oral anticoagulants. Appropriate monitoring should be undertaken when anticoagulants are prescribed concurrently. Adjustments in the dose of oral anticoagulants may be necessary to maintain the desired level of anticoagulation.

Changes in liver function tests have been observed in some patients receiving AUGMENTIN. The clinical significance of these changes is uncertain but AUGMENTIN should be used with caution in patients with evidence of hepatic dysfunction.

Cholestatic jaundice, which may be severe, but is usually reversible, has been reported rarely. Signs and symptoms may not become apparent for up to six weeks after treatment has ceased.

In patients with renal impairment AUGMENTIN dosage should be adjusted as recommended in the Dosage and Administration section.

In patients with reduced urine output, crystalluria has been observed very rarely, predominantly with parenteral therapy. During the administration of high doses of amoxicillin, it is advisable to maintain adequate fluid intake and urinary output in order to reduce the possibility of amoxicillin crystalluria (see Overdose).

AUGMENTIN suspensions contain 2.5 mg aspartame per 1 ml, which is a source of phenylalanine, and therefore should be used with caution in patients with phenylketonuria.

**Interactions**

Concomitant use of probenecid is not recommended. Probenecid decreases the renal tubular secretion of amoxicillin. Concomitant use with AUGMENTIN may result in increased and prolonged blood levels of amoxicillin but not of clavulanate.

Concomitant use of allopurinol during treatment with amoxicillin can increase the likelihood of allergic skin reactions. There are no data on the concomitant use of AUGMENTIN and allopurinol.

In common with other antibiotics, AUGMENTIN may affect the gut flora, leading to lower oestrogen reabsorption and reduced efficacy of combined oral contraceptives.

In the literature there are rare cases of increased international normalised ratio in patients maintained on acenocoumarol or warfarin and prescribed a course of amoxicillin. If co-
administration is necessary, the prothrombin time or international normalised ratio should be carefully monitored with the addition or withdrawal of AUGMENTIN.

In patients receiving mycophenolate mofetil, reduction in pre-dose concentration of the active metabolite mycophenolic acid of approximately 50% has been reported following commencement of oral amoxicillin plus clavulanic acid. The change in pre-dose level may not accurately represent changes in overall MPA exposure.

**Pregnancy and Lactation**

Reproduction studies in animals (mice and rats) with orally and parenterally administered AUGMENTIN have shown no teratogenic effects. In a single study in women with pre-term, premature rupture of the foetal membrane (pPROM), it was reported that prophylactic treatment with AUGMENTIN may be associated with an increased risk of necrotising enterocolitis in neonates. As with all medicines, use should be avoided in pregnancy, especially during the first trimester, unless considered essential by the physician.

AUGMENTIN may be administered during the period of lactation. With the exception of the risk of sensitisation, associated with the excretion of trace quantities in breast milk, there are no detrimental effects for the infant.

**Effects on Ability to Drive and Use Machines**

Adverse effects on the ability to drive or operate machinery have not been observed.

**Adverse Reactions**

Data from large clinical trials were used to determine the frequency of very common to rare undesirable effects. The frequencies assigned to all other undesirable effects (i.e., those occurring at <1/10,000) were mainly determined using post-marketing data and refer to a reporting rate rather than a true frequency.

The following convention has been used for the classification of frequency:

- **very common** ≥1/10
- **common** ≥1/100 and <1/10
- **uncommon** ≥1/1000 and <1/100
- **rare** ≥1/10,000 and <1/1000
- **very rare** <1/10,000.

**Infections and infestations**

Common Mucocutaneous candidiasis
**Blood and lymphatic system disorders**

**Rare**
- Reversible leucopenia (including neutropenia) and thrombocytopenia

**Very rare**
- Reversible agranulocytosis and haemolytic anaemia. Prolongation of bleeding time and prothrombin time

**Immune system disorders**

**Very rare**
- Angioneurotic oedema, anaphylaxis, serum sickness-like syndrome, hypersensitivity vasculitis

**Nervous system disorders**

**Uncommon**
- Dizziness, headache

**Very rare**
- Reversible hyperactivity and convulsions. Convulsions may occur in patients with impaired renal function or in those receiving high doses.

**Gastrointestinal disorders**

**Common**
- Diarrhoea, nausea, vomiting

Nausea is more often associated with higher oral dosages. If gastrointestinal reactions are evident, they may be reduced by taking AUGMENTIN at the start of a meal.

**Uncommon**
- Indigestion

**Very rare**
- Antibiotic-associated colitis (including pseudomembranous colitis and haemorrhagic colitis – see Warnings and Precautions).

Black hairy tongue

Superficial tooth discolouration has been reported very rarely in children. Good oral hygiene may help to prevent tooth discolouration as it can usually be removed by brushing.

**Hepatobiliary disorders**

**Uncommon**
- A moderate rise in AST and/or ALT has been noted in patients treated with beta-lactam class antibiotics, but the significance of these findings is unknown

**Very rare**
- Hepatitis and cholestatic jaundice. These events have been noted with other penicillins and cephalosporins.

Hepatic events have been reported predominantly in males and elderly patients and may be associated with prolonged treatment. These events have been very rarely reported in children.
Signs and symptoms usually occur during or shortly after treatment but in some cases may not become apparent until several weeks after treatment has ceased. These are usually reversible. Hepatic events may be severe and in extremely rare circumstances, deaths have been reported. These have almost always occurred in patients with serious underlying disease or taking concomitant medications known to have the potential for hepatic effects.

**Skin and subcutaneous tissue disorders**

Uncommon  
Skin rash, pruritus, urticaria

Rare  
Erythema multiforme

Very rare  
Stevens-Johnson syndrome, toxic epidermal necrolysis, bullous exfoliative-dermatitis, acute generalised exanthemous pustulosis (AGEP), and drug reaction with eosinophilia and systemic symptoms (DRESS)

If any hypersensitivity dermatitis reaction occurs, treatment should be discontinued.

**Renal and urinary disorders**

Very rare  
Interstitial nephritis, crystalluria (see *Overdose*)

**Overdose**

Gastrointestinal symptoms and disturbance of the fluid and electrolyte balances may be evident. Gastrointestinal symptoms may be treated symptomatically with attention to the water electrolyte balance.

Amoxicillin crystalluria, in some cases leading to renal failure, has been observed (see *Warnings and Precautions*).

*Augmentin* may be removed from the circulation by haemodialysis.

**Pharmacological Properties**

**Pharmacodynamics**

Resistance to many antibiotics is caused by bacterial enzymes which destroy the antibiotic before it can act on the pathogen. The clavulanate in *Augmentin* infant drops anticipates this defence mechanism by blocking the β-lactamase enzymes, thus rendering the organisms susceptible to amoxicillin's rapid bactericidal effect at concentrations readily attainable in the body.

Clavulanate by itself has little antibacterial activity; however, in association with amoxicillin as *Augmentin* it produces an antibiotic agent of broad spectrum with wide application in hospital and general practice.
In the list below, organisms are categorised according to their *in vitro* susceptibility to *AUGMENTIN*.

**In vitro susceptibility of micro-organisms to AUGMENTIN**

Where clinical efficacy of *AUGMENTIN* has been demonstrated in clinical trials this is indicated with an asterisk (*). Organisms that do not produce beta-lactamase are identified (with †). If an isolate is susceptible to amoxicillin, it can be considered susceptible to *AUGMENTIN*.

**Commonly susceptible species**

<table>
<thead>
<tr>
<th>Gram-positive aerobes:</th>
</tr>
</thead>
<tbody>
<tr>
<td><em>Bacillus anthracis</em></td>
</tr>
<tr>
<td><em>Enterococcus faecalis</em></td>
</tr>
<tr>
<td><em>Listeria monocytogenes</em></td>
</tr>
<tr>
<td><em>Nocardia asteroides</em></td>
</tr>
<tr>
<td><em>Streptococcus pyogenes</em>†</td>
</tr>
<tr>
<td><em>Streptococcus agalactiae</em>†</td>
</tr>
<tr>
<td>*Streptococcus spp. (other β-hemolytic)†</td>
</tr>
<tr>
<td><em>Staphylococcus aureus</em> (methylillin susceptible)*</td>
</tr>
<tr>
<td><em>Staphylococcus saprophyticus</em> (methylillin susceptible)</td>
</tr>
<tr>
<td>Coagulase negative staphylococcus (methylillin susceptible)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Gram-negative aerobes:</th>
</tr>
</thead>
<tbody>
<tr>
<td><em>Bordetella pertussis</em></td>
</tr>
<tr>
<td><em>Haemophilus influenzae</em></td>
</tr>
<tr>
<td><em>Haemophilus parainfluenzae</em></td>
</tr>
<tr>
<td><em>Helicobacter pylori</em></td>
</tr>
<tr>
<td><em>Moraxella catarrhalis</em>§</td>
</tr>
<tr>
<td><em>Neisseria gonorrhoeae</em></td>
</tr>
<tr>
<td><em>Pasteurella multocida</em></td>
</tr>
<tr>
<td><strong>Vibrio cholerae</strong></td>
</tr>
<tr>
<td>---------------------</td>
</tr>
<tr>
<td><strong>Other:</strong></td>
</tr>
<tr>
<td><em>Borrelia burgdorferi</em></td>
</tr>
<tr>
<td><em>Leptospira icterohaemorrhagiae</em></td>
</tr>
<tr>
<td><em>Treponema pallidum</em></td>
</tr>
<tr>
<td><strong>Gram positive anaerobes:</strong></td>
</tr>
<tr>
<td><em>Clostridium</em> spp.</td>
</tr>
<tr>
<td><em>Peptococcus niger</em></td>
</tr>
<tr>
<td><em>Peptostreptococcus magnus</em></td>
</tr>
<tr>
<td><em>Peptostreptococcus micros</em></td>
</tr>
<tr>
<td><em>Peptostreptococcus</em> spp.</td>
</tr>
<tr>
<td><strong>Gram-negative anaerobes:</strong></td>
</tr>
<tr>
<td><em>Bacteroides fragilis</em></td>
</tr>
<tr>
<td><em>Bacteroides</em> spp.</td>
</tr>
<tr>
<td><em>Capnocytophaga</em> spp.</td>
</tr>
<tr>
<td><em>Eikenella</em> corrodens</td>
</tr>
<tr>
<td><em>Fusobacterium nucleatum</em></td>
</tr>
<tr>
<td><em>Fusobacterium</em> spp.</td>
</tr>
<tr>
<td><em>Porphyromonas</em> spp.</td>
</tr>
<tr>
<td><em>Prevotella</em> spp.</td>
</tr>
</tbody>
</table>

**Species for which acquired resistance may be a problem**
### Gram-negative aerobes:

- *Escherichia coli*
- *Klebsiella oxytoca*
- *Klebsiella pneumoniae* *
- *Klebsiella* spp.
- *Proteus mirabilis*
- *Proteus vulgaris*
- *Proteus* spp.
- *Salmonella* spp.
- *Shigella* spp.

### Gram-positive aerobes:

- *Corynebacterium* spp.
- *Enterococcus faecium*
- *Streptococcus pneumoniae* †
- Viridans group streptococcus

### Inherently resistant organisms

**Gram-negative aerobes:**

- *Acinetobacter* spp.
- *Citrobacter freundii*
- *Enterobacter* spp.
- *Hafnia alvei*
- *Legionella pneumophila*
- *Morganella morganii*
- *Providencia* spp.
- *Pseudomonas* spp.
- *Serratia* spp.
Stenotrophomas maltophilia

Yersinia enterolitica

Others:

Chlamydia pneumoniae

Chlamydia psittaci

Chlamydia spp.

Coxiella burnetti

Mycoplasma spp.

**Pharmacokinetics**

The pharmacokinetics of the two components of *AUGMENTIN* are closely matched. Peak serum levels of both occur about 1 hour after oral administration. Absorption of *AUGMENTIN* is optimised at the start of a meal.

Doubling the dosage of *AUGMENTIN* approximately doubles the serum levels achieved.

Both clavulanate and amoxicillin have low levels of serum binding; about 70% remains free in the serum.

**Pre-clinical Safety Data**

No further information of relevance.

**PHARMACEUTICAL PARTICULARS**

**List of Excipients**

Xanthum gum, hydroxypropyl methylcellulose, aspartame, silicon dioxide, colloidal silica, succinic acid, raspberry, orange and golden syrup dry flavours.

**Incompatibilities**

None known.

**Shelf Life**

The expiry date is indicated on the packaging.
Special Precautions for Storage

The dry powder should be stored in unopened containers in a dry place at below 25°C. Reconstituted suspensions should be stored in a refrigerator (2-8°C) and used within seven days.

Nature and Contents of Container

Glass bottles with screw caps, containing an off-white dry powder. A syringe dosing device is also included.

Instructions for Use/Handling

- Check cap seal is intact before use.
- Invert and shake bottle to loosen powder.
- Fill the bottle with water to just below the mark on bottle label.
- Invert and shake well, then top up with water to the mark. Invert and shake again.
- Allow to stand for 5 minutes to ensure full dispersion.
- Shake well before taking each dose.

If a syringe is provided:

Once reconstituted, the adaptor that is supplied with the syringe dosing device should be inserted into the neck of the bottle before replacing the screw cap.

Not all presentations are available in every country.

Version number: GDS23/IPI12

Date of issue: 15 August 2017

Trade marks are owned by or licensed to the GSK group of companies.